留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

King cobra peptide OH-CATH30 as a potential candidate drug through clinic drug-resistant isolates

Feng Zhao Xin-Qiang Lan Yan Du Pei-Yi Chen Jiao Zhao Fang Zhao Wen-Hui Lee Yun Zhang

Feng Zhao, Xin-Qiang Lan, Yan Du, Pei-Yi Chen, Jiao Zhao, Fang Zhao, Wen-Hui Lee, Yun Zhang. King cobra peptide OH-CATH30 as a potential candidate drug through clinic drug-resistant isolates. Zoological Research, 2018, 39(2): 87-96. doi: 10.24272/j.issn.2095-8137.2018.025
Citation: Feng Zhao, Xin-Qiang Lan, Yan Du, Pei-Yi Chen, Jiao Zhao, Fang Zhao, Wen-Hui Lee, Yun Zhang. King cobra peptide OH-CATH30 as a potential candidate drug through clinic drug-resistant isolates. Zoological Research, 2018, 39(2): 87-96. doi: 10.24272/j.issn.2095-8137.2018.025

眼镜王蛇多肽OH-CATH30可作为潜在候选药物分子杀死临床耐药菌

doi: 10.24272/j.issn.2095-8137.2018.025
基金项目: This work was supported by grants from the National Natural Sciences Foundation of China(31572268, 31560596), the Key Research Program of the Chinese Academy of Sciences (KJZD-EW-L03), "Yunnan Scholar" Program, the Yunnan Applied Basic Research Projects (2016FD076), the National Training Program of Innovation and Entrepreneurship for Undergraduates (201510685001, 201610685001), and Puer University (RCXM003 & CXTD011)
详细信息
    通讯作者:

    Feng Zhao,Yun Zhang,E-mail: zhaofeng@mail.kiz.ac.cn; zhangy@mail.kiz.ac.cn

  • 中图分类号:  

King cobra peptide OH-CATH30 as a potential candidate drug through clinic drug-resistant isolates

Funds: This work was supported by grants from the National Natural Sciences Foundation of China(31572268, 31560596), the Key Research Program of the Chinese Academy of Sciences (KJZD-EW-L03), "Yunnan Scholar" Program, the Yunnan Applied Basic Research Projects (2016FD076), the National Training Program of Innovation and Entrepreneurship for Undergraduates (201510685001, 201610685001), and Puer University (RCXM003 & CXTD011)
More Information
    Corresponding author: Feng Zhao,Yun Zhang,E-mail: zhaofeng@mail.kiz.ac.cn; zhangy@mail.kiz.ac.cn
  • 摘要: 阳离子抗菌肽(antimicrobial peptides ,AMPs)被认为是一类重要的临床治疗药物的候选分子,它对细菌、真菌和部分病毒都具有有效的杀菌活性。基于我们此前的研究结果,眼镜王蛇cathelicidin(OH-CATH)是由34个氨基酸组成的多肽,具有很强的抑菌活性和较低的溶血活性。我们的研究目的是为了评价D型和L型 OH-CATH30和常用抗生素的临床病原菌抗菌活性。研究中共收集到584株临床病原菌(时间在2013–2016),根据国际CLSI标准用微量肉汤稀释法,来评价抗菌肽和常用抗生素的杀菌效果。这些临床病原菌中,85%对D型和L型OH-CATH30敏感。与常用抗生素相比,D型和L型OH-CATH30对革兰氏阳性菌具有较强的抑菌活性,并且对几乎所有的革兰氏阴性菌都具有很好的杀菌效果。尤其是对不动杆菌属,包括多重耐药鲍曼不动杆菌和甲氧西林耐药金黄色葡萄球菌,具有非常高的杀菌活性。总体而言,D型和L型OH-CATH30的抑菌活性要强于9种常用抗生素。因此,OH-CATH30是一种非常有前景的药物候选分子,可以用来治疗各种常规抗生素耐药菌引起的感染。
  • 加载中
计量
  • 文章访问数:  1745
  • HTML全文浏览量:  577
  • PDF下载量:  539
  • 被引次数: 0
出版历程
  • 收稿日期:  2017-12-01
  • 修回日期:  2018-02-08
  • 刊出日期:  2018-03-18

目录

    /

    返回文章
    返回